【摘要】 目的：探讨卵巢癌抗独特型单链抗体６Ｂ１１ｓｃＦｖ／ｈＧＭＣＳＦ融合蛋白质（６Ｂ１１ＧＭ）作为肿瘤疫苗的可能性。方法：采用体外Ｔ细胞增殖试验，对６Ｂ１１ＧＭ刺激Ｔ细胞的能力进行测定，并用流式细胞仪对Ｔ细胞表型及ＡＰＣＭＨＣⅡ表达情况进行测定，测定了外周血单个核细胞经６Ｂ１１ＧＭ激活后对卵巢癌细胞系的非ＭＨＣ限制的杀伤活性。结果：６Ｂ１１ＧＭ及６Ｂ１１均能引起特异的Ｔ细胞增殖，但６Ｂ１１ＧＭ组的增殖明显高于６Ｂ１１组，以ＣＤ４＋增殖为主。６Ｂ１１ＧＭ能明显增加抗原提呈细胞（ａｎｔｉｇｅｎｐｒｅｓｅｎｔｉｎｇｃｅｌ，ＡＰＣ）的ＭＨＣⅡ表达，使ＡＰＣ更有效地摄取抗原，激活非ＭＨＣ限制的杀伤活性。结论：６Ｂ１１ＧＭ能引起细胞免疫反应，作为疫苗具有良好的前景更多还原

【Abstract】 Objective: To explore the possibility of an anti idiotypic antibody/human GM CSF fusion protein (6B11 GM) used as tumor vaccine for ovarian cancer. Methods: In vitro T cell proliferation to determine the capacity of 6B11 GM to stimulating T cells; T cell phenotype and the MHC Ⅱ expression of antigen presenting cell (APC) were determined with flow cytometry. Cytotoxity of primed mononuclear cells was investigated using trypan blue with the ovarian cancer cell line SKOV3 and the K562 as target cells. Results: Both 6B11 and 6B11 GM could stimulate special T cell proliferation, however 6B11 GM was advanced at the proliferation level. CD4 + T cells were predominate among the proliferation cells. 6B11 GM could significantly enhance the MHC Ⅱ expression of APC. An in vitro non MHC restricted cytotoxic function could be effectively activated with 6B11 GM and 6B11. When compared with 6B11, 6B11 GM was more likely to be taken up by APC. Conclusion: 6B11 GM can stimulate cellular immunity, and therefore may be used as tumor vaccine for ovarian cancer.更多还原